# Cells 2019, 8, 659

# References

1. Singh, B.; Read, S.; Asseman, C.; Malmstrom, V.; Mottet, C.; Stephens, L.A.; Stepankova, R.; Tlaskalova, H.; Powrie, F. Control of intestinal inflammation by regulatory T cells. Immunol. Rev. 2001, 182, 190–200. [CrossRef] [PubMed]
2. Tlaskalova-Hogenova, H.; Tuckova, L.; Stepankova, R.; Hudcovic, T.; Palova-Jelinkova, L.; Kozakova, H.; Rossmann, P.; Sanchez, D.; Cinova, J.; Hrncir, T.; et al. Involvement of innate immunity in the development of inflammatory and autoimmune diseases. Ann. N. Y. Acad. Sci. 2005, 1051, 787–798. [CrossRef] [PubMed]
3. Rabizadeh, S.; Rhee, K.J.; Wu, S.; Huso, D.; Gan, C.M.; Golub, J.E.; Wu, X.; Zhang, M.; Sears, C.L. Enterotoxigenic bacteroides fragilis: A potential instigator of colitis. Inflamm. Bowel Dis. 2007, 13, 1475–1483. [CrossRef] [PubMed]
4. Mahida, Y.R.; Makh, S.; Hyde, S.; Gray, T.; Borriello, S.P. Effect of Clostridium difficile toxin A on human intestinal epithelial cells: Induction of interleukin 8 production and apoptosis after cell detachment. Gut 1996, 38, 337–347. [CrossRef] [PubMed]
5. Brito, G.A.; Fujji, J.; Carneiro-Filho, B.A.; Lima, A.A.; Obrig, T.; Guerrant, R.L. Mechanism of Clostridium difficile toxin A-induced apoptosis in T84 cells. J. Infect. Dis. 2002, 186, 1438–1447. [CrossRef] [PubMed]
6. Ghia, J.E.; Blennerhassett, P.; Deng, Y.; Verdu, E.F.; Khan, W.I.; Collins, S.M. Reactivation of inflammatory bowel disease in a mouse model of depression. Gastroenterology 2009, 136, 2280–2288. [CrossRef] [PubMed]
7. Zamani, S.; Hesam Shariati, S.; Zali, M.R.; Asadzadeh Aghdaei, H.; Sarabi Asiabar, A.; Bokaie, S.; Nomanpour, B.; Sechi, L.A.; Feizabadi, M.M. Detection of enterotoxigenic Bacteroides fragilis in patients with ulcerative colitis. Gut Pathog. 2017, 9, 53. [CrossRef] [PubMed]
8. Issa, M.; Vijayapal, A.; Graham, M.B.; Beaulieu, D.B.; Otterson, M.F.; Lundeen, S.; Skaros, S.; Weber, L.R.; Komorowski, R.A.; Knox, J.F.; et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2007, 5, 345–351. [CrossRef]
9. Baumgart, M.; Dogan, B.; Rishniw, M.; Weitzman, G.; Bosworth, B.; Yantiss, R.; Orsi, R.H.; Wiedmann, M.; McDonough, P.; Kim, S.G.; et al. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn’s disease involving the ileum. ISME J. 2007, 1, 403–418. [CrossRef]
10. Darfeuille-Michaud, A.; Boudeau, J.; Bulois, P.; Neut, C.; Glasser, A.L.; Barnich, N.; Bringer, M.A.; Swidsinski, A.; Beaugerie, L.; Colombel, J.F. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology 2004, 127, 412–421. [CrossRef]
11. Ford, D.E.; Erlinger, T.P. Depression and C-reactive protein in US adults: Data from the Third National Health and Nutrition Examination Survey. Arch. Intern. Med. 2004, 164, 1010–1014. [CrossRef] [PubMed]
12. Tuglu, C.; Kara, S.H.; Caliyurt, O.; Vardar, E.; Abay, E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology 2003, 170, 429–433. [CrossRef] [PubMed]
13. De Punder, K.; Pruimboom, L. Stress induces endotoxemia and low-grade inflammation by increasing barrier permeability. Front. Immunol. 2015, 6, 223. [CrossRef] [PubMed]
14. Whitehead, W.E.; Palsson, O.; Jones, K.R. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications? Gastroenterology 2002, 122, 1140–1156. [CrossRef] [PubMed]
15. Loftus, E.V., Jr.; Guerin, A.; Yu, A.P.; Wu, E.Q.; Yang, M.; Chao, J.; Mulani, P.M. Increased risks of developing anxiety and depression in young patients with Crohn’s disease. Am. J. Gastroenterol. 2011, 106, 1670–1677. [CrossRef] [PubMed]
16. Targownik, L.E.; Sexton, K.A.; Bernstein, M.T.; Beatie, B.; Sargent, M.; Walker, J.R.; Graff, L.A. The Relationship Among Perceived Stress, Symptoms, and Inflammation in Persons With Inflammatory Bowel Disease. Am. J. Gastroenterol. 2015, 110, 1001–1012. [CrossRef] [PubMed]
17. Coskun, M.; Vermeire, S.; Nielsen, O.H. Novel Targeted Therapies for Inflammatory Bowel Disease. Trends Pharmacol. Sci. 2017, 38, 127–142. [CrossRef]
18. Torres, J.; Ellul, P.; Langhorst, J.; Mikocka-Walus, A.; Barreiro-de Acosta, M.; Basnayake, C.; Ding, N.J.S.; Gilardi, D.; Katsanos, K.; Moser, G.; et al. European Crohn’s and Colitis Organisation Topical Review on Complementary Medicine and Psychotherapy in Inflammatory Bowel Disease. J. Crohns Colitis 2019, 13, 673–685e. [CrossRef]
19. Regueiro, M.; Greer, J.B.; Szigethy, E. Etiology and Treatment of Pain and Psychosocial Issues in Patients With Inflammatory Bowel Diseases. Gastroenterology 2017, 152, 430–439 e434. [CrossRef]